Details of the SBP
| General Information of Synthetic Binding Protein (SBP) (ID: SBP000152) | ||||||
|---|---|---|---|---|---|---|
| SBP Name |
BiTE AMG-910
|
|||||
| Synonyms |
AMG910
|
|||||
| Design Method | Traditional methods (Site-directed mutagenesis and/or Directed evolution) | |||||
| Highest Status | Phase I | |||||
| Protein Scaffold Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| Scaffold ID | PS018 | [1] | ||||
| Scaffold Name | BiTE | |||||
| Scaffold Class | Antibody fragment | |||||
| Fold Type | Beta-Sheets + Loops | |||||
| Binding Target(s) of This SBP (BTS) |
|---|
| BTS Name | Details | Mechanism | Application | Affinity | Research Organization | Ref |
|---|---|---|---|---|---|---|
| T-cell surface glycoprotein CD3 | Stimulator | Gastric cancer [ICD-11: 2B72.Z]; Gastroesophageal Junction Cancer [ICD-11: 2B71.Z] | N.A. | Amgen | [1] | |
| Claudin-18 | Stimulator | Gastric cancer [ICD-11: 2B72.Z]; Gastroesophageal Junction Cancer [ICD-11: 2B71.Z] | N.A. | Amgen | [1] | |
| Clinical Trial Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| NCT04260191 | Click to show the Detail | |||||
| Indication | Claudin 18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma | |||||
| Phase | Phase I | |||||
| Title | A Global Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 910 in Subjects With Claudin 18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma | |||||
| Status | Recruiting | |||||
| Sponsor | Amgen | |||||